ClinicalTrials.gg
CompletedNCT05306379Statin-DDIUpdated Apr 20, 2022

Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin

A Phase 1 interventional study of Simvastatin and Voclosporin in Drug-drug Interaction, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-20.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A single-center, open-label, Phase 1, drug-drug interaction study to investigate the effect of voclosporin on the pharmacokinetics of simvastatin and simvastatin acid in healthy volunteers.

02

Conditions studied

  • Drug-drug Interaction

Keywords

  • voclosporin
  • simvastatin
  • pharmacokinetics
  • drug effects
  • drug interactions
03

In context

Lead sponsor

Aurinia Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Healthy male or female subjects aged >=18 and \<=55 years
  • >=18.0 and \<32 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Abnormal and/or prolonged
  • Subjects using nicotine products within 3 months prior to screening
  • Subjects who have lost or donated >450 mL of whole blood or blood products within 30 days prior to the Screening Visit.
  • Use of any prescription medication within 14 days prior to the first dose of study medication, or any over-the-counter products (including natural health products, e.g., food supplements, vitamins, herbal supplements) within 7 days prior to the first dose of study medication, except for topical products without significant systemic absorption.
  • Use of any drugs or substances known to induce or inhibit hepatic drug metabolism within 28 days prior to administration of the study medication
  • Consumption of grapefruit or grapefruit juice, pomelo or star fruit within 7 days of first dose of study drug on Day 1
  • Use of hormonal or hormone replacement therapy within 14 days prior to first dose of study drug.
  • No COVID-19 vaccines are allowed within 28 days prior to first dose of study drug.
  • History of or current alcohol abuse or drug addiction
  • Subjects who are pregnant or breast feeding
  • Subjects who have received any drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to screening.
  • Subjects who have any significant health issues as deemed by their treating physician/investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Voclosporin/Simvastatin

    Subjects will receive a single oral dose of 40 mg simvastatin (given as two 20 mg tablets) in the morning of Day 1 and Day 8. Subjects will receive voclosporin administered as an oral 23.7 mg dose (three 7.9 mg capsules) twice-daily for 7 days from the morning of Day 2 until the evening of Day 8.

    Drug: Simvastatin · Drug: Voclosporin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of simvastatin and simvastatin acid (Cmax)

    To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Maximum observed concentration (Cmax).

    Time frame: 9 days

  2. Pharmacokinetics of simvastatin and simvastatin acid (AUC)

    To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Area under the concentration-time curve (AUC) from time zero to infinity.

    Time frame: 9 days

  3. Pharmacokinetics of simvastatin and simvastatin acid (AUC)

    To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Area under the concentration-time curve (AUC) time zero to last quantifiable concentration.

    Time frame: 9 days

Secondary outcomes

  1. Pharmacokinetics of voclosporin (Cmax)

    To evaluate voclosporin blood concentrations - Cmax.

    Time frame: 9 days

  2. Pharmacokinetics of voclosporin (AUC)

    To evaluate voclosporin blood concentrations - AUC from time zero to 12 hours.

    Time frame: 9 days

  3. Pharmacokinetics of voclosporin (Tmax)

    To evaluate voclosporin blood concentrations - Time to reach maximum observed plasma concentration (Tmax).

    Time frame: 9 days

  4. Pharmacokinetics of voclosporin (Ctrough)

    To evaluate voclosporin blood concentrations - Trough concentration (Ctrough) at the end of a dosing interval at steady state.

    Time frame: 9 days

  5. Pharmacokinetics of voclosporin (CL/F)

    To evaluate voclosporin blood concentrations - apparent clearance (CL/F).

    Time frame: 9 days

  6. Number of participants with abnormal laboratory test results

    Number of subjects with abnormal laboratory test results (eg., hematology, biochemistry and urinalysis) will be assessed

    Time frame: Up to 2 weeks

  7. Number of participants with abnormal vital signs

    Number of participants with abnormal vital signs (eg., blood pressure, heart rate, body temperature, respiratory rate) will be assessed

    Time frame: Up to 2 weeks

  8. 12-Lead Electrocardiogram Assessment

    Standard 12-lead electrocardiograms (eg., QTcF interval) will be summarized by observed value and change from baseline values.

    Time frame: Up to 2 weeks

07

Study locations

1 site
  • Labcorp Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Apr 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Apr 1, 2022
StartActual
Jan 24, 2022
Primary completionActual
Apr 5, 2022
CompletionActual
Apr 5, 2022
Last update
Apr 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05306379
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
Jan 24, 2022
Primary completion
Apr 5, 2022
Completion
Apr 5, 2022
Last update
Apr 20, 2022

Study contacts

Winnie Lim
study director · Aurinia Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Simvastatin · Voclosporin

Start the discussion